Linaclotide

Overview

Linaclotide is a structural mimic of the endogenous GC-C agonists guanylin and uroguanylin, stabilized by three disulfide bonds. It acts locally at the apical surface of intestinal epithelial cells and is essentially not absorbed systemically, so its effects and safety are largely confined to the gut.

By activating GC-C, linaclotide raises intracellular and extracellular cyclic GMP, which opens the CFTR chloride channel and increases secretion of chloride and bicarbonate into the intestinal lumen; water follows, softening stool and accelerating transit. Extracellular cGMP is also thought to reduce firing of pain-sensing afferent nerves, contributing to relief of abdominal pain in IBS-C. In the pivotal phase 3 trials, linaclotide significantly increased the frequency of complete spontaneous bowel movements versus placebo in chronic constipation.

The most common adverse effect is diarrhea, which can be dose-limiting. It carries a boxed warning against use in young pediatric patients due to a risk of serious dehydration seen in juvenile animal studies.

Mechanism of Action

GC-C activation increases intracellular cyclic GMP, which activates protein kinase G II to phosphorylate and open the CFTR channel, driving secretion of chloride and bicarbonate and passive water movement into the gut lumen. The resulting increase in luminal fluid softens stool and accelerates colonic transit. cGMP that exits into the submucosa is proposed to dampen the activity of pain-sensing sensory neurons, accounting for linaclotide's benefit on abdominal pain in IBS-C. Its minimal systemic absorption keeps activity localized to the intestine.